Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France
Clicks: 751
ID: 110586
2003
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
751 views
223 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #1 of 581 articles by views in pediatrics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 581 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The rates of PAEs and musculoskeletal PAEs were higher for the FQ group than the control group. This observation supports the American Academy of Pediatrics statement restricting off-label FQ use in pediatric patients to second-line treatment in a limited number of situations.
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.